Cardax Inc
OTC:CDXI

Watchlist Manager
Cardax Inc Logo
Cardax Inc
OTC:CDXI
Watchlist
Price: 0.0001 USD Market Closed
Market Cap: $80.3

Net Margin

-1 085.4%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-1 085.4%
=
Net Income
$-5.4m
/
Revenue
$500.7k

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-1 085.4%
=
Net Income
$-5.4m
/
Revenue
$500.7k

Peer Comparison

Country Company Market Cap Net
Margin
US
Cardax Inc
OTC:CDXI
80.3 USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
972.2B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547.5B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.1B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.4B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
272.1B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
148.3B USD
Loading...
FR
Sanofi SA
PAR:SAN
93.8B EUR
Loading...

Market Distribution

Lower than 94% of companies in the United States of America
Percentile
6th
Based on 15 072 companies
6th percentile
-1 085.4%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Cardax Inc
Glance View

Market Cap
80.3 USD
Industry
Pharmaceuticals

Cardax, Inc. is a development stage biopharmaceutical company, which engages in development of pharmaceuticals for chronic diseases driven by inflammation. The company is headquartered in Honolulu, Hawaii and currently employs 10 full-time employees. The company went IPO on 2012-01-30. The firm has a commercial business unit that markets dietary supplements for inflammatory health. The firm's product platform consists of CDX-101, astaxanthin pharmaceutical candidate, that is being developed for cardiovascular inflammation and dyslipidemia, with a target initial indication of severe hypertriglyceridemia. CDX-301, the Company’s zeaxanthin pharmaceutical candidate, is being developed for macular degeneration. Its pharmaceutical candidates are in pre-clinical development, including the planning of investigational new drug (IND) enabling studies. ZanthoSyn is a physician recommended astaxanthin dietary supplement for inflammatory health. The firm sells ZanthoSyn primarily through wholesale and e-commerce channels.

CDXI Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-1 085.4%
=
Net Income
$-5.4m
/
Revenue
$500.7k
How has Net Margin changed over time?

Over the last 1 years, Cardax Inc’s Net Margin has decreased from -716.3% to -1 085.4%. During this period, it reached a low of -1 085.4% on May 1, 2021 and a high of -716.3% on Dec 1, 2019.

Back to Top